TABLE 2.
Group | Baseline | 4th week | 6th week | 10th week | |
---|---|---|---|---|---|
fT3 | ML | 6.09 ± 0.75 | 6.39 ± 0.54 | 5.61 ± 0.85 | 3.8 ± 0.59*** |
MH | 5.76 ± 0.59 | 5.66 ± 0.46 | 4.56 ± 0.32** | 3.82 ± 0.62*** | |
PL | 6.84 ± 0.63 | 6.14 ± 0.71 | 5.97 ± 0.63* | 4.88 ± 0.49*** | |
PH | 5.42 ± 0.45 | 6 ± 0.87 | 5.21 ± 0.48 | 4.43 ± 0.7** | |
ATDs | 6.06 ± 0.8 | 6.05 ± 0.69 | 5.43 ± 0.78** | 4.35 ± 0.73*** | |
fT4 | ML | 19.9 ± 2.03 | 19.47 ± 2.69 | 17.68 ± 1.67* | 14.87 ± 2.49** |
MH | 20.97 ± 3.06 | 18.53 ± 1.81 | 13.49 ± 2.32** | 13.61 ± 1.34*** | |
PL | 21.42 ± 2.06 | 19.76 ± 2.26 | 19.7 ± 2.86 | 16.15 ± 2.37*** | |
PH | 19.73 ± 3.03 | 20.81 ± 2.23 | 17.14 ± 2.48 | 14.48 ± 3.02** | |
ATDs | 20.53 ± 2.54 | 19.68 ± 2.3 | 17.38 ± 3.07*** | 14.92 ± 2.48*** | |
TSH | ML | 11.68 ± 2.18 | 12.72 ± 1.28 | 13.4 ± 1.71 | 15.01 ± 2.17* |
MH | 11.62 ± 0.92 | 13.33 ± 1.85* | 13.69 ± 1.56* | 16.77 ± 2.93** | |
PL | 9.66 ± 1.8 | 12.06 ± 1.97* | 10.03 ± 1.06 | 12.39 ± 2.16* | |
PH | 11.29 ± 1.41 | 10.9 ± 1.48 | 14.1 ± 1.64** | 14.15 ± 0.92*** | |
ATDs | 11.01 ± 1.78 | 12.22 ± 1.83* | 12.66 ± 2.23** | 14.25 ± 2.54*** | |
Weight | ML | 237.67 ± 10.87 | 244.44 ± 16.44 | 232.98 ± 16.95 | 238.73 ± 7.8 |
MH | 228.51 ± 15.07 | 230.11 ± 21.67 | 227.62 ± 25.31 | 219.68 ± 15.93 | |
PL | 230.79 ± 11.66 | 224.58 ± 18.48 | 210.3 ± 20.29* | 199.9 ± 13.46*** | |
PH | 244.77 ± 8.74 | 223.46 ± 11.67** | 205.31 ± 15.27*** | 194.83 ± 15.18*** | |
Control 1 | 248.6 ± 12.38 | 280.88 ± 15.5* | 287.28 ± 9.6** | 319.25 ± 8.84*** |
The Wilcoxon rank-sum test was used to compare these parameters and values are expressed as the mean ± SD. Statistical difference from corresponding baseline expressed as p values: *p < 0 .05, **p < 0 .01, ***p < 0.001.